COVID-19

Coronavirus and flu: Why COVID-19 poses more of a threat 

People line up to buy hand sanitiser and masks at a government pharmacy store in Bangkok, Thailand, March 6, 2020. REUTERS/Soe Zeya Tun - RC23EF9CNC6C

More than 80,000 worldwide have caught the coronavirus. Image: REUTERS/Soe Zeya Tun

Tom Duszynski
Director Epidemiology Education, IUPUI
Share:
Our Impact
What's the World Economic Forum doing to accelerate action on COVID-19?
The Big Picture
Explore and monitor how COVID-19 is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:

COVID-19

  • COVID-19 produces signs and symptoms that are similar to influenza, which makes it difficult to distinguish between the two.
  • The death rate of the seasonal flu varies but is about 0.1% compared to about 2% for COVID-19.
  • Coronavirus is more contagious: each person with it is likely to spread it to two others, compared to a rate of roughly half for flu.

The spread of the new coronavirus, which has infected over 80,000 people worldwide and resulted in the death of more than 3,000, has raised alarms around the world.

Figure 2. Epidemic curve of confirmed COVID-19 cases reported outside of China (n=24,727), by date of report and WHO region through 08 March 2020.
The number of coronavirus cases has surpassed 100,000 worldwide. Image: World Health Organization

At the same time, the seasonal influenza, known as the flu, causes severe illness in between 3 million and 5 million people, with hundreds of thousands of deaths every year worldwide.

Have you read?

With so many fewer cases than the flu, what explains the dramatic response to COVID-19 and worry around the globe? And how would a person know whether seasonal influenza-like symptoms are COVID-19?

As an epidemiologist, here’s how I look at these questions.

Difficult to distinguish

The first thing to realize is that the emergence of the novel coronavirus isn’t a rare “black swan” event. Rather, this is a product of evolution; there have been about 40 new, infectious diseases discovered globally since the 1970s, with pathogens often jumping from animals to humans.

Detecting who has this new virus becomes a key public health challenge, which is made harder because it’s the season for another virus – influenza. And in the U.S., there is a shortage of local laboratories able to test for the coronavirus virus in humans.

Loading...

Influenza, by contrast, is far more familiar to public health researchers and doctors, and thus more predictable. It can occur anytime during the year in the U.S., but it typically begins in September and can go into May of the following year. While the peak of cases in the U.S. fluctuates, it typically occurs in February when the disease is widespread across the country.

If a new disease emerges during influenza season and has different signs and symptoms than the influenza, then it is easier to detect and track in the human population. However, if the signs and symptoms overlap, as they do with flu and COVID-19, detection is much more difficult for the public health, medical and the lay population.

COVID-19 produces signs and symptoms that are similar to influenza, which makes it difficult to distinguish between the two. COVID-19 can cause fever, cough, body aches, fatigue and, occasionally, vomiting and diarrhea; both can cause pneumonia as well.

Speed of spread

Currently one of the biggest differences between seasonal influenza and COVID-19 is the incubation period – that is, the time from exposure to development of signs and symptoms. For seasonal influenza, the incubation period ranges from one to four days, but in some instances, people may be contagious a day before symptoms appear and as long as five to seven days after symptoms start. COVID-19’s incubation period ranges from 2-14 days, which is up to three times longer than influenza.

Also, COVID-19 is more contagious than seasonal influenza. The average person, even with mild symptoms, is likely to spread the disease to more than two people. By contrast, the seasonal flu’s rate is roughly half.

Another significant challenge with influenza and COVID-19 is that they both can have mild infections. People with more mild disease are less likely to seek diagnosis and care, but are still considered infectious and able to transmit the disease person to person.

The death rate of the seasonal flu varies year to year but is about 0.1%, compared to about 2% for COVID-19. The disastrous 1918 influenza epidemic, known as the “Spanish flu,” had a death rate of about 2.5%.

Finally, one of the biggest concerns for COVID-19 is asymptomatic infections. People who are infected with the virus may be able to transmit the infection, and yet they themselves don’t have any signs or symptoms of disease. This represents a challenge because it would be difficult to identify persons that need to be tested for the disease since they have no signs or symptoms, but their ability to transmit the disease would allow for amplification in a naive, or uninfected, population.

No vaccine available for COVID-19

Unlike influenza, COVID-19 does not have a vaccine or medication people can take to protect themselves and it is believed that everyone is susceptible.

There are a number of efforts to develop treatments for COVID-19, but nothing is yet approved. Vaccines are also being pursued, but a vaccine for COVID-19 will not be ready for several months.

Getting the vaccine for the seasonal flu can actually be helpful for medical professionals. Since the signs and symptoms are similar, if everyone were to be vaccinated against the flu, fewer people would have the flu, thus making it easier to detect another disease with similar symptoms. The faster it is identified, the faster public health and the medical community can respond to minimize the spread of disease.

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Related topics:
COVID-19Global HealthGlobal Governance
Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

Winding down COVAX – lessons learnt from delivering 2 billion COVID-19 vaccinations to lower-income countries

Charlotte Edmond

January 8, 2024

About Us

Events

Media

Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum